Eisai R&d Management Co., Ltd.

Tadashi Kadowaki

Yasuhiro Funahashi

Junji Matsui

Taro Semba

Atsumi Yamaguchi

Yusuke Adachi

Jason S Simon

Lucy Xu

Pallavi Sachdev

Yusuke Narita

Kazuhiko Yamada

Kentaro Takahashi

Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds

Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.

Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds

Growing community of inventors

Tsukuba, Japan

Tadashi Kadowaki